使用天花中和试验评估天花疫苗
Evaluation of smallpox vaccines using variola neutralization.
作者信息
Damon Inger K, Davidson Whitni B, Hughes Christine M, Olson Victoria A, Smith Scott K, Holman Robert C, Frey Sharon E, Newman Frances, Belshe Robert B, Yan Lihan, Karem Kevin
机构信息
Centers for Disease Control and Prevention, National Center for Zoonotic, Vector-borne, and Enteric Diseases, Division of Viral and Rickettsial Diseases, 1600 Clifton Road NE, Atlanta, GA 30333, USA.
Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, Edward A. Doisy Research Center, 8th Floor, 1100 S. Grand Blvd, St Louis, MO 63104, USA.
出版信息
J Gen Virol. 2009 Aug;90(Pt 8):1962-1966. doi: 10.1099/vir.0.010553-0. Epub 2009 Apr 1.
Abstract
The search for a 'third'-generation smallpox vaccine has resulted in the development and characterization of several vaccine candidates. A significant barrier to acceptance is the absence of challenge models showing induction of correlates of protective immunity against variola virus. In this light, virus neutralization provides one of few experimental methods to show specific 'in vitro' activity of vaccines against variola virus. Here, we provide characterization of the ability of a modified vaccinia virus Ankara vaccine to induce variola virus-neutralizing antibodies, and we provide comparison with the neutralization elicited by standard Dryvax vaccination.
摘要
对“第三代”天花疫苗的探索已促成了几种候选疫苗的研发及特性研究。疫苗被接受的一个重大障碍是缺乏能显示诱导针对天花病毒保护性免疫相关指标的攻毒模型。鉴于此，病毒中和试验是为数不多的能证明疫苗针对天花病毒具有特异性“体外”活性的实验方法之一。在此，我们阐述了一种改良安卡拉痘苗病毒疫苗诱导天花病毒中和抗体的能力，并与标准Dryvax疫苗接种所引发的中和反应进行了比较。
相似文献
1
Evaluation of smallpox vaccines using variola neutralization.使用天花中和试验评估天花疫苗
J Gen Virol. 2009 Aug;90(Pt 8):1962-1966. doi: 10.1099/vir.0.010553-0. Epub 2009 Apr 1.
2
Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.天花疫苗的天花病毒和牛痘病毒中和试验分析
Clin Vaccine Immunol. 2012 Jul;19(7):1116-8. doi: 10.1128/CVI.00056-12. Epub 2012 May 16.
3
Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for immunogenicity assessment.天花疫苗蚀斑减少中和试验：免疫原性评估的实验室优化及验证方法
J Immunol Methods. 2025 Jan;536:113787. doi: 10.1016/j.jim.2024.113787. Epub 2024 Dec 12.
4
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.在小鼠模型中，用改良安卡拉痘苗病毒和已获许可的天花疫苗Dryvax联合接种所赋予的增强免疫原性和保护作用。
Virology. 2005 Sep 1;339(2):164-75. doi: 10.1016/j.virol.2005.06.002.
5
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.LC16m8，一种减毒天花疫苗在从未接种过牛痘的成年人中的安全性和免疫原性。
J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.
6
Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.痘苗病毒糖蛋白B5上的主要中和位点在天花病毒直系同源物B6上的暴露方式不同。
J Virol. 2007 Aug;81(15):8131-9. doi: 10.1128/JVI.00374-07. Epub 2007 May 23.
7
Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.第三代天花疫苗：临床天花缺失带来的挑战。
Future Microbiol. 2010 Sep;5(9):1367-82. doi: 10.2217/fmb.10.98.
8
Smallpox vaccines: targets of protective immunity.天花疫苗：保护性免疫的靶标。
Immunol Rev. 2011 Jan;239(1):8-26. doi: 10.1111/j.1600-065X.2010.00975.x.
9
The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.非复制型天花候选疫苗痘苗病毒李斯特株缺陷型（dVV-L）和改良痘苗病毒安卡拉株（MVA）可引发强大的长期保护作用。
Virology. 2005 Oct 10;341(1):91-101. doi: 10.1016/j.virol.2005.06.043.
10
Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.非复制型天花候选疫苗在小鼠体内诱导的短期和长期免疫原性及保护作用，并与传统第一代疫苗进行比较。
Vaccine. 2008 Mar 25;26(14):1794-804. doi: 10.1016/j.vaccine.2007.12.059. Epub 2008 Feb 12.
引用本文的文献
1
Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines.基于非复制型和复制型痘苗病毒的疫苗所诱导的猴痘免疫和牛痘免疫差异。
Vaccines (Basel). 2025 May 14;13(5):520. doi: 10.3390/vaccines13050520.
2
Optimizing Microneutralization and IFN-γ ELISPOT Assays to Evaluate Mpox Immunity.优化微量中和试验和IFN-γ ELISPOT试验以评估猴痘免疫力。
Vaccines (Basel). 2024 Dec 31;13(1):27. doi: 10.3390/vaccines13010027.
3
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine.MVA-BN 的冻干和液冻制剂作为天花和猴痘疫苗的等效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2384189. doi: 10.1080/21645515.2024.2384189. Epub 2024 Aug 22.
4
Biology of Variola Virus.天花病毒生物学。
Adv Exp Med Biol. 2024;1451:139-149. doi: 10.1007/978-3-031-57165-7_9.
5
Development of a novel serological assay for the detection of mpox infection in vaccinated populations.开发一种新型血清学检测方法，用于检测接种人群中的猴痘感染。
J Med Virol. 2023 Oct;95(10):e29134. doi: 10.1002/jmv.29134.
6
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.单次和双剂量接种改良安卡拉牛痘疫苗-巴伐利亚北欧株可诱导持久的 B 细胞记忆应答，与复制天花疫苗相当。
J Infect Dis. 2023 May 12;227(10):1203-1213. doi: 10.1093/infdis/jiac455.
7
Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus.基于牛痘病毒的疫苗有望引发对 2022 年猴痘病毒的高度交叉反应性免疫。
Viruses. 2022 Sep 3;14(9):1960. doi: 10.3390/v14091960.
8
Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks.猴痘疫情中天花疫苗和抗病毒药物的重新定位潜力：关于比较效益和风险的快速综述
Health Sci Rep. 2022 Aug 23;5(5):e798. doi: 10.1002/hsr2.798. eCollection 2022 Sep.
9
Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence?如果可能出现类似天花的疾病，我们做好准备了吗？
Viruses. 2017 Aug 27;9(9):242. doi: 10.3390/v9090242.
10
Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans.塞罗2病毒凸显了一种感染人类的天然痘苗病毒的基本基因组和生物学特征。
Viruses. 2016 Dec 10;8(12):328. doi: 10.3390/v8120328.
本文引用的文献
1
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.多次接种IMVAMUNE（安卡拉痘苗病毒株）后再接受Dryvax攻击的临床和免疫反应。
Vaccine. 2007 Dec 12;25(51):8562-73. doi: 10.1016/j.vaccine.2007.10.017. Epub 2007 Oct 26.
2
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.通过蛋白质组芯片进行抗体谱分析显示，减毒天花疫苗安卡拉痘苗病毒的免疫原性与Dryvax相当。
J Virol. 2008 Jan;82(2):652-63. doi: 10.1128/JVI.01706-07. Epub 2007 Oct 31.
3
Correlates of protective immunity in poxvirus infection: where does antibody stand?痘病毒感染中保护性免疫的相关因素：抗体处于何种地位？
Immunol Cell Biol. 2008 Jan;86(1):80-6. doi: 10.1038/sj.icb.7100118. Epub 2007 Oct 9.
4
Antibody responses to vaccinia membrane proteins after smallpox vaccination.天花疫苗接种后针对牛痘膜蛋白的抗体反应。
J Infect Dis. 2007 Jul 15;196(2):220-9. doi: 10.1086/518793. Epub 2007 Jun 4.
5
Proteome-wide analysis of the serological response to vaccinia and smallpox.针对牛痘和天花血清学反应的全蛋白质组分析。
Proteomics. 2007 May;7(10):1678-86. doi: 10.1002/pmic.200600926.
6
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.佐剂增强的针对重组蛋白的抗体反应与小鼠和猴子对正痘病毒攻击的保护作用相关。
Vaccine. 2007 Apr 12;25(15):2787-99. doi: 10.1016/j.vaccine.2006.12.037. Epub 2007 Jan 3.
7
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination.针对痘苗病毒两种感染形式的多种抗原的抗体反应定量为天花疫苗接种提供了一个基准。
Nat Med. 2006 Nov;12(11):1310-5. doi: 10.1038/nm1457. Epub 2006 Nov 5.
8
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.IMVAMUNE作为第三代天花疫苗的候选产品，其安全性和免疫原性。
Vaccine. 2006 Mar 15;24(12):2065-70. doi: 10.1016/j.vaccine.2005.11.022. Epub 2005 Nov 28.
9
Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy.意大利天花疫苗接种后牛痘病毒抗体的流行情况。
J Gen Virol. 2005 Nov;86(Pt 11):2955-2960. doi: 10.1099/vir.0.81265-0.
10
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.痘苗病毒H3L包膜蛋白是人类中和抗体的主要靶标，并能引发针对小鼠致死性攻击的保护作用。
J Virol. 2005 Sep;79(18):11724-33. doi: 10.1128/JVI.79.18.11724-11733.2005.
Zotero 插件